The company acknowledged that 'fever camera' sales were improving its profits but did not disclose specific figures, although it announced it is consolidating its thermal division. However, a surge in gross margins shows the profits from fever camera sales.
Amidst all this remains the question for how long and how much will fever cameras bolster the company's growth.
IMO this is really a question of when the FDA and other international government agencies wake up. At that point the knowledge we're being exposed to on IPVM will begin to roll out to the end users, driving demand down further.